New chemo cocktail shows promise against aggressive childhood cancer

This study tested a combination of two chemotherapy drugs, irinotecan and carboplatin, as the first treatment for children and adults newly diagnosed with intermediate- or high-risk rhabdomyosarcoma, a type of muscle cancer. The goal was to see if this drug pair could shrink tumors and be given safely before standard therapy. The trial enrolled 65 participants and focused on response rates, side effects, and local tumor control.